Piero Volpi1, Raul Zini2, Franz Erschbaumer3, Michelangelo Beggio4, Alberto Busilacchi5, Giulia Carimati1. 1. Humanitas Clinical and Research Center, Via Alessandro Manzoni, 56, 20089 Rozzano, Milan, Italy. 2. Maria Cecilia Hospital - Cotignola, Via Madonna di Genova, 1, 48033 Cotignola, Ravenna, Italy. 3. Bressanone/Brixen Hospital, Via Dante, 51, I-39042 Bressanone, Bolzano, Italy. 4. Policlinico San Marco, Via Francesco Zanotto, 40, 30173 Mestre, Venice, Italy. 5. Maria Cecilia Hospital - Cotignola, Via Madonna di Genova, 1, 48033 Cotignola, Ravenna, Italy. albertobusilacchi@yahoo.it.
Abstract
PURPOSE: Knee osteoarthritis (OA) is a musculoskeletal disorder that may have a heavy impact on the patients' quality of life. Intra-articular collagen injection may be a safe adjuvant. Recently, CHondroGrid (CG), a hydrolyzed (< 3 kDa) bovine collagen injectable formulation, has been placed on the market. The aim of this study was to investigate the safety and performance profile of CG. METHODS: Patients affected by Kellgren Lawrence grade 1 to 4 knee OA and BMI < 30 were treated by administering three CG injections of 2 ml (4 mg) each (at 15 days and 45 days from the first one, respectively) and were followed up for six months after the last administration. Clinical records were retrospectively assessed to compare VAS, Lequesne and WOMAC total, pain, stiffness, and physical function scores collected at baseline and 15, 45, and 225 days after the first injection. RESULTS: At the last follow-up, 70 patients (37 men and 33 women, aged 57.1 ± 14.5 years) treated with CG showed a 50% reduction in their median Lequesne score, a 50% reduction in their VAS score at rest and moving, and a ≥ 50% reduction for all other scores under consideration. CONCLUSIONS: CG may be a safe and effective adjuvant in the treatment of symptomatic knee OA.
PURPOSE: Knee osteoarthritis (OA) is a musculoskeletal disorder that may have a heavy impact on the patients' quality of life. Intra-articular collagen injection may be a safe adjuvant. Recently, CHondroGrid (CG), a hydrolyzed (< 3 kDa) bovine collagen injectable formulation, has been placed on the market. The aim of this study was to investigate the safety and performance profile of CG. METHODS:Patients affected by Kellgren Lawrence grade 1 to 4 knee OA and BMI < 30 were treated by administering three CG injections of 2 ml (4 mg) each (at 15 days and 45 days from the first one, respectively) and were followed up for six months after the last administration. Clinical records were retrospectively assessed to compare VAS, Lequesne and WOMAC total, pain, stiffness, and physical function scores collected at baseline and 15, 45, and 225 days after the first injection. RESULTS: At the last follow-up, 70 patients (37 men and 33 women, aged 57.1 ± 14.5 years) treated with CG showed a 50% reduction in their median Lequesne score, a 50% reduction in their VAS score at rest and moving, and a ≥ 50% reduction for all other scores under consideration. CONCLUSIONS:CG may be a safe and effective adjuvant in the treatment of symptomatic knee OA.
Authors: Raveendhara R Bannuru; Christopher H Schmid; David M Kent; Elizaveta E Vaysbrot; John B Wong; Timothy E McAlindon Journal: Ann Intern Med Date: 2015-01-06 Impact factor: 25.391
Authors: Marita Cross; Emma Smith; Damian Hoy; Sandra Nolte; Ilana Ackerman; Marlene Fransen; Lisa Bridgett; Sean Williams; Francis Guillemin; Catherine L Hill; Laura L Laslett; Graeme Jones; Flavia Cicuttini; Richard Osborne; Theo Vos; Rachelle Buchbinder; Anthony Woolf; Lyn March Journal: Ann Rheum Dis Date: 2014-02-19 Impact factor: 19.103
Authors: Bruno R da Costa; Stephan Reichenbach; Noah Keller; Linda Nartey; Simon Wandel; Peter Jüni; Sven Trelle Journal: Lancet Date: 2017-07-08 Impact factor: 79.321
Authors: Johanne Martel-Pelletier; Andrew J Barr; Flavia M Cicuttini; Philip G Conaghan; Cyrus Cooper; Mary B Goldring; Steven R Goldring; Graeme Jones; Andrew J Teichtahl; Jean-Pierre Pelletier Journal: Nat Rev Dis Primers Date: 2016-10-13 Impact factor: 52.329
Authors: Beth Woods; Andrea Manca; Helen Weatherly; Pedro Saramago; Eleftherios Sideris; Christina Giannopoulou; Stephen Rice; Mark Corbett; Andrew Vickers; Matthew Bowes; Hugh MacPherson; Mark Sculpher Journal: PLoS One Date: 2017-03-07 Impact factor: 3.240